Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Debt (2016 - 2025)

Cumberland Pharmaceuticals' Total Debt history spans 15 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Total Debt fell 65.69% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, down 65.69%, while the annual FY2025 figure was $5.2 million, 65.69% down from the prior year.
  • Total Debt for Q4 2025 was $5.2 million at Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $20.0 million in Q1 2022 and bottomed at $5.2 million in Q1 2025.
  • The 5-year median for Total Debt is $15.0 million (2021), against an average of $13.6 million.
  • The largest annual shift saw Total Debt soared 35.71% in 2022 before it crashed 67.43% in 2025.
  • A 5-year view of Total Debt shows it stood at $15.0 million in 2021, then grew by 8.0% to $16.2 million in 2022, then decreased by 20.23% to $12.9 million in 2023, then rose by 18.21% to $15.3 million in 2024, then crashed by 65.69% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Total Debt are $5.2 million (Q4 2025), $5.2 million (Q3 2025), and $5.2 million (Q2 2025).